MUMBAI,
India and WARREN,
N.J., May 22, 2024 /PRNewswire/ -- Cipla Limited
(BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla")
and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla"),
today announced that it has received the final approval for its
Abbreviated New Drug Application (ANDA) for Lanreotide Injection
120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the United States
Food and Drug Administration (USFDA).
Cipla's Lanreotide Injection is AP-rated therapeutic equivalent
generic version of Somatuline® Depot (Lanreotide) Injection.
Lanreotide Injection is supplied as 120 mg/0.5 mL, 90 mg/0.3 mL, 60
mg/0.2 mL single-dose, pre-filled, ready-to-inject syringe. Cipla's
Lanreotide injection is indicated for the treatment of patients
with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors
(GEP-NETs).
According to IQVIA (IMS Health), Somatuline® Depot (Lanreotide)
had US sales of approximately $898M
for the 12-month period ending March
2024.
About Cipla:
Established in 1935, Cipla is a global pharmaceutical
company focused on agile and sustainable growth, complex generics,
and deepening portfolio in our home markets of India, South
Africa, North America, and
key regulated and emerging markets. Our strengths in the
respiratory, anti-retroviral, urology, cardiology, anti-infective,
and CNS segments are well-known. Our 47 manufacturing sites around
the world produce 50+ dosage forms and 1,500+ products using
cutting-edge technology platforms to cater to our 80+ markets.
Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Feb'24), 1st in the pharma
prescription market in South
Africa (IQVIA MAT Feb'24), and 4th largest by prescription
in the US Gx inhalation products (IQVIA MAT Feb'23). For over eight
decades, making a difference to patients has inspired every aspect
of Cipla's work. Our paradigm-changing offer of a triple
anti-retroviral therapy in HIV/AIDS at less than a dollar a day in
Africa in 2001 is widely
acknowledged as having contributed to bringing inclusiveness,
accessibility, and affordability to the centre of the HIV movement.
A responsible corporate citizen, Cipla's humanitarian approach to
healthcare in pursuit of its purpose of 'Caring for Life' and
deep-rooted community links wherever it is present make it a
partner of choice to global health bodies, peers, and all
stakeholders.
For more, please visit https://www.cipla.com, or click on
Twitter, Facebook, LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cipla-receives-final-approval-for-the-generic-version-of-somatuline-depot-lanreotide-injection-120-mg-0-5-ml-90-mg0-3-ml-60-mg0-2-ml-302153357.html
SOURCE Cipla